Association between plasma PCSK9 and gamma-glutamyl transferase levels in diabetic patients

Atherosclerosis

Volumn 211, Issue 2, 2010, Pages 700-702

  Cariou, Bertrand ^a,b,c   Le Bras, Maëlle ^a,b,c   Langhi, Cédric ^a,b   Le May, Cédric ^a,b   Guyomarc'h Delasalle, Béatrice ^a   Krempf, Michel ^a,b,c   Costet, Philippe ^a,c  

^a INSERM   (France)

^b UNIVERSITÉ DE NANTES   (France)

^c L INSTITUT DU THORAX   (France)

Author keywords

Diabetes; Gamma glutamyl transferase; PCSK9

Indexed keywords

GAMMA GLUTAMYLTRANSFERASE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; SERINE PROTEINASE; UNCLASSIFIED DRUG;

ARTICLE; BODY MASS; ENZYME BLOOD LEVEL; FEMALE; GROUPS BY AGE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SEX DIFFERENCE; SYSTOLIC BLOOD PRESSURE;

BLOOD PRESSURE; CHOLESTEROL; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GAMMA-GLUTAMYLTRANSFERASE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; PROSPECTIVE STUDIES; RECEPTORS, LDL; REGRESSION ANALYSIS; SERINE ENDOPEPTIDASES;

EID: 77955269479     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2010.04.015     Document Type: Article

References (15)

1. Costet P., Krempf M., Cariou B. PCSK9 and LDL cholesterol: unravelling the target to design the bullet. Trends Biochem Sci 2008, 33:426-434.
2. Costet P., Cariou B., Lambert G., et al. Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory-element binding protein 1c. J Biol Chem 2006, 281:6211-6218.
3. Persson L., Galman C., Angelin B., Rudling M. Importance of proprotein convertase subtilisin/kexin type 9 in the hormonal and dietary regulation of rat liver low-density lipoprotein receptors. Endocrinology 2009, 150:1140-1146.
4. Langhi C., Le M.C., Gmyr V., et al. PCSK9 is expressed in pancreatic delta-cells and does not alter insulin secretion. Biochem Biophys Res Commun 2009, 390:1288-1293.
5. Mbikay M., Sirois F., Mayne J., et al. PCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities. FEBS Lett 2009, 584:701-706.
6. Baass A., Dubuc G., Tremblay M., et al. Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents. Clin Chem 2009, 55:1637-1645.
7. Dubuc G., Tremblay M., Pare G., Jacques H., Hamelin J., Benjannet S., et al. A new method for measurement of total plasma PCSK9: clinical applications. J Lipid Res 2010, 51:140-149.
8. Lakoski S.G., Lagace T.A., Cohen J.C., Horton J.D., Hobbs H.H. Plasma levels of PCSK9 in a large multiethnic population. J Clin Endocrinol Metab 2009.
9. Alborn W.E., Cao G., Careskey H.E., et al. Serum proprotein convertase subtilisin kexin type 9 is correlated directly with serum LDL cholesterol. Clin Chem 2007, 53:1814-1819.
10. Thamer C., Tschritter O., Haap M., et al. Elevated serum GGT concentrations predict reduced insulin sensitivity and increased intrahepatic lipids. Horm Metab Res 2005, 37:246-251.
11. Fraser A., Harris R., Sattar N., Ebrahim S., Smith G.D., Lawlor D.A. Gamma-glutamyltransferase is associated with incident vascular events independently of alcohol intake: analysis of the British Women's Heart and Health Study and meta-analysis. Arterioscler Thromb Vasc Biol 2007, 27:2729-2735.
12. Lee D.S., Evans J.C., Robins S.J., et al. Gamma glutamyl transferase and metabolic syndrome, cardiovascular disease, and mortality risk: the Framingham Heart Study. Arterioscler Thromb Vasc Biol 2007, 27:127-133.
13. Paolicchi A., Emdin M., Passino C., et al. LDL-associated serum gamma-glutamyltransferase in patients with coronary atherosclerosis. Atherosclerosis 2006, 186:80-85.
14. Lambert G., Ancellin N., Charlton F., et al. Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment. Clin Chem 2008, 54:1038-1045.
15. Cohen J.C., Boerwinkle E., Mosley T.H., Hobbs H.H. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006, 354:1264-1272.